Gere Sunder–Plassmann

Research interests

Publications

• A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(22)01841-4

• Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

  Clinical Pharmacology & Therapeutics · 2016 · 10.1002/cpt.602

• Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

  Journal of Medical Genetics · 2016 · https://doi.org/10.1136/jmedgenet-2016-104178

• Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

  Orphanet Journal of Rare Diseases · 2015 · https://doi.org/10.1186/s13023-015-0253-6

• Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

  PLoS Medicine · 2014 · 10.1371/journal.pmed.1001750

• Dialysate Sodium Concentration and the Association with Interdialytic Weight Gain, Hospitalization, and Mortality

  Clinical Journal of the American Society of Nephrology · 2011 · 10.2215/cjn.05440611

• Predialysis Serum Sodium Level, Dialysate Sodium, and Mortality in Maintenance Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

  American Journal of Kidney Diseases · 2011 · 10.1053/j.ajkd.2011.07.013

• Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)61493-8

• Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey

  Journal of Medical Genetics · 2009 · https://doi.org/10.1136/jmg.2008.065904

• Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis

  Nature Medicine · 2008 · 10.1038/nm.1874

• Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey

  European Heart Journal · 2007 · https://doi.org/10.1093/eurheartj/ehm153

• Fabry disease and the skin: data from FOS, the Fabry outcome survey

  British Journal of Dermatology · 2007 · https://doi.org/10.1111/j.1365-2133.2007.08002.x

• Fabry Disease: Perspectives from 5 Years of FOS

  · 2006

• Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey

  Acta Paediatrica · 2005 · 10.1080/08035250500275022

• Fabry disease: overall effects of agalsidase alfa treatment

  European Journal of Clinical Investigation · 2004 · https://doi.org/10.1111/j.1365-2362.2004.01424.x

• Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients

  Journal of the American Society of Nephrology · 2004 · 10.1097/01.asn.0000124671.61963.1e

• Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

  European Journal of Clinical Investigation · 2004 · 10.1111/j.1365-2362.2004.01309.x

• High prevalence of hyperhomocysteinemia in critically ill patients

  Critical Care Medicine · 2000 · 10.1097/00003246-200004000-00013

• Molecular biology of 5,10-methylenetetrahydrofolate reductase.

  PubMed · 2000

• Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.

  Journal of the American Society of Nephrology · 1998 · 10.1681/asn.v94655

• Importance of iron supply for erythropoietin therapy

  Nephrology Dialysis Transplantation · 1995 · 10.1093/ndt/10.11.2070

Current projects

No projects listed.